Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
CAMP compared with NERV: revenue, margins and what each company keeps, and the suppliers and customers both name
CAMP
Camp4 Therapeutics Corp
Change
Mkt cap
Revenue
Revenue
NERV
Minerva Neurosciences, Inc.
Change
Mkt cap
Revenue
Revenue
vs
Compare
CAMP
Camp4 Therapeutics Corp
vs
NERV
Minerva Neurosciences, Inc.
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Revenue flow
Desk
News
Calendar
Saved
Search
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Price
Supply-chain overlap
Revenue flow
CAMP: latest quarter is a loss; flow not drawable. NERV: latest quarter not drawable.
Method
›
Supply-chain overlap
direct ties · both sides
Sources
›
direct ties · both sides
Only CAMP
7
LLY
Eli Lilly
customer
BMRN
BioMarin Pharmaceutical
customer
FULC
Fulcrum Therapeutics
customer
GSK
GlaxoSmithKline Intellectual Property (No. 3)
customer
3 more · CAMP chain
›
Shared
0
No shared counterparties.
Only NERV
7
RPRX
Royalty Pharma plc ("Royalty Pharma")
customer
—
Catalent
unlisted
supplier
—
Catalent Germany Schorndorf GmbH
unlisted
supplier
Role chip = supplier or customer
—
= no ticker (unlisted)
Source: SEC EDGAR
—
Dr. Inderjit Kaul
unlisted
supplier
3 more · NERV chain
›
CAMP
Camp4 Therapeutics Corp
Change
3.77
▼
−1.48%
· post 3.77
Mkt cap
$221.9M
Revenue
$2M
Q2 FY26
Revenue
$3M
FY25
NERV
Minerva Neurosciences, Inc.
Change
2.54
▲
+8.09%
· post 2.54
Closed
Nov 4 '26
Mkt cap
$112.2M
Revenue
—
Revenue
—
vs
Compare
Closed
Nov 4 '26
CAMP
Camp4 Therapeutics Corp
vs
NERV
Minerva Neurosciences, Inc.
3.77
▼
−1.48%
post 3.77
Price
2.54
▲
+8.09%
post 2.54
$221.9M
Mkt cap
$112.2M
Q2 FY26
$2M
Revenue
—
FY25
$3M
Revenue
—
Change
Change
CAMP
3.77
▼
−1.48%
vs
NERV
2.54
▲
+8.09%
Closed
Nov 4 '26
Price
rebased to 0%
1D
1W
1M
3M
YTD
1Y
5Y
1D
1W
1M
3M
YTD
1Y
5Y
CAMP, solid
NERV, dashed